A mass vaccination campaign is usually described as a supply problem: get doses to the right place, keep them cold, and get needles into arms before potency lapses. That framing leaves out a second workstream that has to be built with the same rigor and staffed from day one — adverse events following immunization, or AEFI, surveillance. It does not compete with cold chain logistics for attention; it runs in parallel, with its own forms, its own reporting lines, and its own failure mode if it is left as an afterthought.
What Counts as an AEFI
An AEFI is any untoward medical occurrence following immunization, whether or not it turns out to be caused by the vaccine. That distinction matters operationally: a health worker filling out a report is not being asked to diagnose a vaccine injury, only to document that something happened after a dose was given. The World Health Organization sorts these events into a small set of categories that a campaign’s clinical staff are trained to recognize — reactions caused by the inherent properties of a correctly administered vaccine, reactions traced to a defect in the product itself, reactions caused by an immunization error such as poor handling or incorrect administration, anxiety-related reactions tied to the injection process rather than the vaccine, and coincidental events that would have happened anyway. Sorting a report into one of these buckets is the job of people downstream of the vaccinator, not the vaccinator in the field.
Why It Cannot Just Ride on the Cold Chain Team
It is tempting to assume that whoever is already tracking vaccine stock and temperature logs can absorb AEFI reporting too. In practice the two workstreams point in opposite directions. Cold chain logistics is about the product: doses on hand, temperature excursions, wastage, and resupply timing, aggregated at the level of a health facility or a district store. AEFI surveillance is about the recipient: an individual patient, a specific batch and lot number, a time of onset, and an outcome, aggregated at the level of a case. The reporting lines diverge just as sharply — stock and temperature data move up a supply chain to logistics managers, while AEFI reports move to national regulatory authorities and pharmacovigilance centers, often on a different form, a different schedule, and with different confidentiality obligations because they carry identifiable patient information. Trying to route both through one clipboard is how a campaign ends up with clean stock ledgers and a silent gap in the one system meant to catch a real safety signal.
The Paper Trail: From Reporting Form to Causality Committee
The mechanics of AEFI surveillance are deliberately standardized so that a report filed in a remote outreach post is usable by people who never see the patient. A reporting form captures patient information, the vaccine’s name, manufacturer, and batch or lot number, the date and time of administration, a description of the event and when it started, an initial seriousness classification, and who is reporting. Serious or clustered reports are escalated to a causality assessment committee — a multidisciplinary group working from a standardized WHO tool that walks through an eligibility check on the diagnosis, a checklist for gathering the available facts, and a decision algorithm that sorts the case as consistent, inconsistent, indeterminate, or unclassifiable with respect to the vaccine. National programs feed the resulting data upward through the WHO/UNICEF Joint Reporting Form on Immunization, which is also how global partners assess a country’s AEFI surveillance capacity rather than just its coverage numbers.
Two Workstreams, One Campaign
| Dimension | Cold Chain / Supply Logistics | AEFI Surveillance |
|---|---|---|
| Unit tracked | Doses, stock, temperature | Individual patient case |
| Core skill set | Inventory, transport, temperature monitoring | Clinical assessment, epidemiological investigation |
| Data destination | Logistics managers, district stores | Regulators, pharmacovigilance centers |
| Failure signature | Stockout, wasted doses | Undetected safety signal, eroded trust |
Why the Gap Is Expensive to Ignore
The cost of skipping this track is not measured in wasted doses. A campaign with a spotless cold chain record can still lose the public if a cluster of adverse events goes unreported or unexplained, because rumor moves faster than a supply report ever will. That is why WHO and UNICEF pair the technical AEFI infrastructure with communication training for national program managers and regulatory staff — the causality committee’s finding is only useful if it reaches caregivers and community leaders before an unverified account does. For anyone planning a mass immunization effort in a humanitarian setting, the practical takeaway is straightforward: budget for AEFI surveillance as its own line item, with its own trained staff and its own reporting chain, rather than treating it as a subtask of the cold chain team that already has a full plate.